CA2654557A1 - Preparations combinees contenant du bifeprunox et de la l-dopa - Google Patents
Preparations combinees contenant du bifeprunox et de la l-dopa Download PDFInfo
- Publication number
- CA2654557A1 CA2654557A1 CA002654557A CA2654557A CA2654557A1 CA 2654557 A1 CA2654557 A1 CA 2654557A1 CA 002654557 A CA002654557 A CA 002654557A CA 2654557 A CA2654557 A CA 2654557A CA 2654557 A1 CA2654557 A1 CA 2654557A1
- Authority
- CA
- Canada
- Prior art keywords
- dopa
- bifeprunox
- administration
- disease
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81405206P | 2006-06-16 | 2006-06-16 | |
EP06115587.5 | 2006-06-16 | ||
US60/814,052 | 2006-06-16 | ||
EP06115587 | 2006-06-16 | ||
PCT/EP2007/055956 WO2007144422A2 (fr) | 2006-06-16 | 2007-06-15 | Préparations combinées contenant du bifeprunox et de la l-dopa |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2654557A1 true CA2654557A1 (fr) | 2007-12-21 |
Family
ID=38691894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002654557A Abandoned CA2654557A1 (fr) | 2006-06-16 | 2007-06-15 | Preparations combinees contenant du bifeprunox et de la l-dopa |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2037964A2 (fr) |
JP (1) | JP2009539942A (fr) |
KR (1) | KR20090033871A (fr) |
AU (1) | AU2007259256A1 (fr) |
CA (1) | CA2654557A1 (fr) |
EA (1) | EA014576B1 (fr) |
IL (1) | IL195493A0 (fr) |
NO (1) | NO20090165L (fr) |
WO (1) | WO2007144422A2 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2496494C2 (ru) * | 2008-06-30 | 2013-10-27 | Новартис Аг | КОМБИНАЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ mGluR, ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ ПАРКИНСОНА |
ITMI20100260A1 (it) * | 2010-02-19 | 2011-08-20 | Giulio Scigliano | Composizione farmaceutica contenente un farmaco per ridurre gli effetti collaterali dei farmaci antipsicotici |
CN105193809B (zh) * | 2010-10-15 | 2019-07-16 | 康特拉医药公司 | 用于治疗运动障碍的血清素受体激动剂组合物 |
US10561618B2 (en) * | 2012-04-18 | 2020-02-18 | Contera Pharma Aps | Orally available pharmaceutical formulation suitable for improved management of movement disorders |
CA2965379A1 (fr) | 2014-10-21 | 2016-04-28 | Abbvie Inc. | Promedicaments de carbidopa et l-dopa et methodes d'utilisation |
EP3481385A1 (fr) | 2016-07-11 | 2019-05-15 | Contera Pharma APS | Système d'administration pulsatile de médicament pour le traitement de l'akinésie matinale |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR045362A1 (es) * | 2003-08-18 | 2005-10-26 | Solvay Pharm Bv | Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-[4-([1,1- bifenil] -3- ilmetil) -1- piperazinil] - 2-(3h) -benzoxazolona |
-
2007
- 2007-06-15 AU AU2007259256A patent/AU2007259256A1/en not_active Abandoned
- 2007-06-15 KR KR1020097001027A patent/KR20090033871A/ko not_active Application Discontinuation
- 2007-06-15 JP JP2009514810A patent/JP2009539942A/ja active Pending
- 2007-06-15 EP EP07730194A patent/EP2037964A2/fr not_active Withdrawn
- 2007-06-15 CA CA002654557A patent/CA2654557A1/fr not_active Abandoned
- 2007-06-15 WO PCT/EP2007/055956 patent/WO2007144422A2/fr active Application Filing
- 2007-06-15 EA EA200970022A patent/EA014576B1/ru not_active IP Right Cessation
-
2008
- 2008-11-25 IL IL195493A patent/IL195493A0/en unknown
-
2009
- 2009-01-12 NO NO20090165A patent/NO20090165L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2009539942A (ja) | 2009-11-19 |
EA200970022A1 (ru) | 2009-06-30 |
WO2007144422A3 (fr) | 2008-03-13 |
EP2037964A2 (fr) | 2009-03-25 |
AU2007259256A1 (en) | 2007-12-21 |
KR20090033871A (ko) | 2009-04-06 |
EA014576B1 (ru) | 2010-12-30 |
NO20090165L (no) | 2009-01-12 |
WO2007144422A2 (fr) | 2007-12-21 |
IL195493A0 (en) | 2009-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Post et al. | Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant response | |
Goldenberg | Medical management of Parkinson’s disease | |
JPH0380127B2 (fr) | ||
JP2008519847A (ja) | 運動障害の治療方法 | |
JP2024050575A (ja) | L-4-クロロキヌレニンの治療的使用 | |
CA2654557A1 (fr) | Preparations combinees contenant du bifeprunox et de la l-dopa | |
US20140271890A1 (en) | Controlled-release pharmaceutical composition | |
AU2017204833A1 (en) | Compositions and methods for treatment of chronic fatigue | |
US7915262B2 (en) | Combination preparations comprising SLV308 and a dopamine agonist | |
WO2010126527A1 (fr) | Méthodes de traitement des affections du snc | |
EP2035002A1 (fr) | Préparations combinées contenant le slv308 et de la l-dopa | |
US8106056B2 (en) | Combination preparations comprising bifeprunox and a dopamine agonist | |
WO2020110128A1 (fr) | Combinaison de pridopidine et d'un agent thérapeutique additionnel pour le traitement de la dyskinésie induite par un médicament | |
JP2519148B2 (ja) | うつ病治療剤 | |
MX2008016226A (es) | Preparaciones de combinacion que comprenden bifeprunox y l-dopa. | |
Schapira et al. | The medical management of Parkinson’s disease | |
MX2008016225A (es) | Preparaciones de combinacion que comprenden slv308 y l-dopa. | |
JP2022071083A (ja) | うつ病を予防または治療するための安息香酸またはその塩および誘導体 | |
OA16802A (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20130617 |